Kancera AB (publ) (KAN.ST) Research

Kancera AB (publ), a biopharmaceutical firm founded in Solna, Sweden, in 2010, specializes in the development of new treatments for inflammatory disorders and various types of cancer, operating both domestically and internationally. The company's pipeline includes several small molecule drug candidates. KAND567 is presently in a Phase IIa clinical trial, assessing its effectiveness against inflammatory heart disease occurring after a heart attack. Additionally, KAND145 is undergoing a Phase I study with healthy volunteers to establish optimal dosing for cancer therapy, alongside a Phase IIa study specifically targeting ovarian cancer. Kancera's research efforts also encompass HDAC inhibitors for managing nerve inflammation and pain, as well as ROR1 inhibitors for addressing solid tumors and blood-related cancers.

Market snapshot

Symbol
KAN.ST
Price
$0.30
Day change
0.00%
Market cap
$3.0M
P/E ratio
-0.06x
52-week range
0.2445-2.25
Sector
Healthcare
Industry
Biotechnology

Peer companies

  • Amniotics AB (publ) (AMNI.ST)
  • Coala-Life Group AB (publ) (COALA.ST)
  • CombiGene AB (publ) (COMBI.ST)
  • Diagonal Bio AB (publ) (DIABIO.ST)
  • Emplicure AB (publ) (EMPLI.ST)
  • FRISQ Holding AB (publ) (FRISQ.ST)
  • Idogen AB (publ) (IDOGEN.ST)
  • NeoDynamics AB (publ) (NEOD.ST)

Open Kancera AB (publ) (KAN.ST) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.